What is AstraZeneca PLC?
AstraZeneca plc is a company that operates in the healthcare, pharmaceutical and biotechnology industry. The global company headquarters were moved to Cambridge in the United Kingdom in 2016 while some of the research and development centres are located in Cambridge, Gaithersburg (United States) and Gothenburg in Sweden. The company has established a network of production facilities in more than a dozen countries with multiple research sites and sales activities in many countries. AstraZeneca plc was formed after the merger in 1999 between Astra AB of Sweden and Zeneca plc from the United Kingdom.
The company's business involves the design, research, production and sale of pharmaceutical and medical products in eight primary areas such as oncology, respiratory, central nervous system, cardiovascular, pain control and anaesthesia, gastrointestinal and infection. AstraZeneca is considered to be among the leading companies in the pharmaceutical industry. Some of the well-known drugs produced by AstraZeneca are Symbicort, Crestor, Tagrisso, Nexium, Pulmicort, Farxiga, Brilinta, Faslodex, Zoladex and Seloken.
AstraZeneca plc is among the top pharmaceutical companies that took the challenge to develop a vaccine to tackle the spread of the Covid-19 pandemic. The vaccine was developed in a partnership with the Oxford University and it is referred to as the “Oxford vaccine”. The interim analysis of the clinical trials exhibited average vaccine effectiveness of slightly above 70 per cent while there was also a result that showed 90 per cent protection. It is stated that the AstraZeneca vaccine is cheaper and has simpler storage requirements. This vaccine comes with an acceptable safety record while serious side effects were not reported. It was also announced that the UK government made a pre-order of 100 million doses whereas AstraZeneca announced the possibility to make a couple of billion doses.
AstraZeneca plc is a publicly-traded company listed on the London, Stockholm and New York stock exchanges with a ticker symbol “AZN”. AZN is also a constituent company in multiple indices such as NASDAQ, FTSE 100 Component and NASDAQ Stockholm.
Performance of the AstraZeneca stock price
The merger of two companies which resulted in the creation of the new AstraZeneca plc, was widely accepted by investors and had a positive effect on the share price of both companies. Since then, the AstraZeneca share price went through a multi-year upward movement followed by occasional downward movements. The trendy movements were interrupted by numerous price pullbacks which bounced towards the original trend. Since its inception the highest price was achieved during the first half of July 2020 when the AstraZeneca stock price fluctuated up to $64 (£48). Looking at the fluctuations in the past couple of years, the AstraZeneca share price shows a clearly defined upward movement. During the last half the decade the AstraZeneca stock price was at its lowest level during the same period in January 2017 reaching a value of slightly below $25 (£18.80).
With certain exceptions, the AstraZeneca share price moves in a defined trend with regular pullbacks followed by higher highs or lower lows in the direction of the trend. Also, relevant factors may even cause short-term range-bound movements.
Gaps up or gaps down a couple of per cents may be noticed on the daily price chart. The AstraZeneca share price may be subject to infrequent price gaps of more than 10 per cent. Although price gaps may also be noticed on the weekly price chart, they might not appear as frequent as the number of gaps evident on the daily chart.
Traders may commonly expect a movement of up to 5 per cent in AstraZeneca share price, with occasional movements of more than 5 per cent during the day. The price may go through slightly higher fluctuations during the week.
How to invest in AstraZeneca stock with tokenised assets
Currency.com has created trading instruments through tokenisation of tradeable assets. Asset tokenisation deals with the creation of tokens which will digitally represent the reference asset by replicating its price movements. The process of creating tokenised assets is enabled with the developments in blockchain technology and the opportunity for creating blockchain tokens. When you invest in AstraZeneca stock through Currency.com tokenised assets platform, you may enjoy an increased level of liquidity, lower costs, shorter settlement time and enhanced risk management. Tokenised shares represent a practical instrument to invest in AstraZeneca stock because it allows traders to make trades directly with crypto. Being able to use their Bitcoin or Ethereum eliminates the financial and non-financial burden associated with the conversion of cryptocurrencies.
Clients trading tokenised assets on the Currency.com platform may use a margin which gives them the possibility to open larger positions with the same amount of capital at their disposal and augment their profitability level. The tokenised AstraZeneca shares are available with a margin of 5 per cent whereas other tokenised assets may have an even lower margin. The margin shows the portion of the trading position value which should be covered with the trader's capital. For instance, a trader with $700 (£528) of available capital can open a position with tokenised AstraZeneca shares worth $14,000 (£10,566). А 2 per cent move in asset price in the right direction may potentially bring $280 (£211). Without the margin, a trader would need to experience a movement of at least 40 per cent change in the underlying asset price to make the same profit of $280 with an initial capital of $700.
Tokenised AstraZeneca stock trading guide
AstraZeneca stock trading on the Currency.com tokenised assets platform is a straightforward process composed of a couple of steps. The process of trading tokenised assets considers the following few steps:
- 1. Register for a trading account on Currency.com platform.
- 2. Choose whether you will fund your account with Bitcoin or Ethereum or if you will deposit fiat money.
- 3. Since Currency.com gives its client the opportunity to trade tokenised assets with a certain margin, you should account for the margin when defining position size.
- 4. Traders take the relevant position with tokenised AstraZeneca shares in the same way as trading any other asset, and a decision should be made between a long or a short position. Currency.com will connect the contrasting trading position among its clients and any remaining orders are hedged through Capital.com or LMAX Digital and other exchanges such as Binance, Bitstamp, Kraken, NASDAQ, NYSE and Gain Capital.
- 5. Positions may be closed at any time by selecting the relevant action or with the creation of take-profit orders. Also, traders need to keep in mind that when opening a position with crypto, they can also withdraw the funds in the associated cryptocurrency.
Why trade tokenised AstraZeneca shares with Currency.com
Tokenised stock trading at the Currency.com tokenised assets exchange has a number of advantages. Tokens are underpinned by robust and immutable blockchain technology. Opening trade will give you a token that tracks and moves according to the underlying instrument's price.
- One-stop crypto trading platform
Trade tokenised AstraZeneca shares with Bitcoin or Ethereum. Benefit from the stock’s price movements without turning your crypto assets into fiat.
Trade tokenised AstraZeneca stocks with a tight market spread, benefit from maker rebates and competitive taker fees.
Experienced traders can trade the world’s top markets, such as AstraZeneca, with up to 1:500 leverage.
- Effective risk management
Manage your risks and secure your profits with stop-loss and take-profit orders. Save your assets with negative balance protection.
We have a scalable and low latency order management system, which can execute 50 million trades per second.
Currency.com operates under new Belarusian regulation with best-in-class AML and KYC laws. Regulatory details and fees are upfront.